Skip to content

Insulet

US · PODD #1561 by market cap Listed 1970
133.17 -4.06 -2.96%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 6.70 Cheap vs history 2nd percentile
5-year average 23.61 · #101 of 126 in Medical Devices
P/E ratio 24.92 Cheap vs history 6th percentile
5-year average 1,814.54 · forward 21.11 · #19 of 39 in Medical Devices
P/S ratio 3.32 Cheap vs history 4th percentile
5-year average 10.32 · forward 2.95 · #80 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Insulet (PODD) 9.24B 21.76 5.85 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value200.00 Economic moatNarrow UncertaintyHigh Capital allocationExemplary

Trading 50.2% below Morningstar's fair value estimate.

Analyst note

Insulet delivered third-quarter results that included constant-currency top-line growth of 20% and adjusted earnings growth of 57%. Gross margin improved by roughly 290 basis points year over year.

Why it matters: These results are largely consistent with what we've come to expect from Insulet: double-digit revenue growth with support from both US and international Omnipod sales. However, we think expected new tubeless patch pump competitors in 2027 are an overhang on the shares. We and the market expect 2027 to look noticeably different for Insulet compared with 2026 and the preceding years. Management hinted that 2027 revenue growth is more likely to hew closer to high single digits rather than the teens. We're pleased to see Insulet take steps to shore up its salesforce, adding clinical retention specialists and tinkering with compensation to reflect retention goals in preparation. Nonetheless, we think it's highly likely that the company will cede share next year.

The bottom line: We've lowered our fair value estimate to $200 per share from $215. This reflects our expectation for narrow-moat Insulet to trail patch pump market growth in 2027 before stabilizing in 2028. The shares remain undervalued, from our perspective. We expect the competitive impact is likely to be greatest next year, even though Omnipod 6 is anticipated to launch. The improvements in this new pump over Omnipod 5 are modest, in our view. In contrast, we think the seven-day wear time for MiniMed's and Tandem's new tubeless patch pumps offers a compelling benefit to users, which should drive adoption.

Long view: For the next couple of years, we think Insulet will be in the unfamiliar position of defending its leadership position in tubeless patch pumps against direct competition. The challenge will be mitigating competitive damage until it can launch its own seven-day pump after 2028.

Fair value

We've lowered our fair value estimate to $200 per share from $215 after trimming our estimates for 2027 and 2028 to reflect stronger competitive inroads by Tandem and MiniMed with their tubeless patch pumps. We now project 8% revenue growth in 2027, which sits in the high-single-digit range that management recently hinted at. This is consistent with how we expect Insulet should grow, but it will trail the high-teens growth we've seen from the tubeless patch pump market as new competitors take share. While we still think the Omnipod’s user-friendly experience could be a positive factor in converting Type 2 patients to pump use, that project is likely to be more challenging now with the anticipated 2027 entry of direct competition from Tandem and MiniMed, which will feature seven-day wear (compared with Omnipod’s three-day wear). We expect Insulet to offer a longer-wear Omnipod in 2028-29. Over the longer term, we anticipate Insulet will move toward better predictive algorithms and the automation of mealtime insulin management to defend its user base.

Since 2012, the firm has made continual progress in bringing down its manufacturing costs (by nearly 2,800 basis points) while increasing its top line. Insulet has also steadily chipped away at its operating costs since it launched its first Omnipod product. We estimate operating margin will reach 18% by 2030 as the firm scales up and reaps operating leverage from its investments in sales and marketing.

Economic moat

Our Narrow Morningstar Economic Moat Rating for Insulet reflects our belief that the firm is more likely than not to deliver normalized excess returns over the next decade. We think its narrow moat stems from intangible assets, which include intellectual property, materials engineering expertise in the somewhat fickle shape-memory alloy technology, as well as experience in manufacturing these complicated devices, and, increasingly over time, predictive algorithms for insulin delivery that improve as more users adopt Omnipod.

Disposable, tubeless patch pumps are trickier to manufacture than traditional tubed insulin pumps, partly because they have more components, creating more opportunities for things to go wrong. We saw some of these manufacturing quality issues surface in 2013-14, when Insulet launched its redesigned Omnipod, which was 30% smaller, and initiated new manufacturing lines at its China facility to meet increased demand for the product. Production problems resulted in greater levels of scrap, increased Omnipod failures for patients, disappointing gross margins, and ultimately, a management change.

Insulet currently holds nearly 900 patents in the US and other key markets, with another 700 applications pending that cover the product’s design, cannula insertion mechanism, software, and the shape-memory alloy drive system. It is this last element that we believe is most critical, as it’s an ingenious application of smart metal technology that expands and contracts to turn gears that drive the plunger and release insulin (versus any sort of motor-based mechanism). We believe this shape memory alloy system is partly what has made it difficult for competitors to create something similar, as this technology is known for some of its limitations (for example, low durability) that have kept it from more extensive commercial applications.

While we think intellectual property is helpful in keeping competitors from getting too close to the specifications of the Omnipod, we also recognize that, among medical technology products, innovation cycles are often short, and new products are commonly commercialized even before existing patents have run their course. For this reason, we think Insulet’s record of rolling out new and improved technology is a significant factor in its narrow moat. Since receiving Food and Drug Administration approval in 2005, Insulet has launched three more generations of pumps that substantially improved wearability, reduced product size and cost, enabled smartphone control, and automated insulin delivery. Its next Omnipod 6 is expected to launch in 2027, followed by the next-gen Omnipod in 2028-29.

The competitive landscape is likely to change once Tandem and MiniMed—both well-established competitors in the Type 1 insulin pump market—enter the tubeless patch pump market in 2027. For the first time, Insulet will need to fend off more direct competition from major companies. However, our research suggests that the Omnipod will still offer a simpler, more user-friendly experience than the upcoming competitive pumps from Tandem and MiniMed two-piece tubeless patch pumps that will feature a durable pump that can be attached to the body with an adhesive patch, and a disposable insulin reservoir.

The Tandem and MiniMed pumps will feature seven-day wear, which could be appealing to certain patients. However, based on the preliminary available information, we think the impending patch pumps from Tandem and MiniMed will still be more complex to use and require the patient to disconnect each time for bathing or swimming (unlike the Omnipod). This sets up several trade-offs for patients, and it's not clear which product advantages will win.

Secondarily, we think there is a degree of patient loyalty to the Omnipod thanks to its tubeless, one-piece, disposable design. Omnipod is “stuck” directly on the body for three days at a time; the waterproof design means the patient can bathe or swim without any worry or disconnecting from the pump. The loyalty to Omnipod is all the more impressive because the pay-as-you-go model of buying from the pharmacy means Omnipod users could easily switch to competitive pumps because they aren’t locked into the four-year durable pump cycle determined by payers.

In terms of environmental, social, and governance matters, Sustainalytics rates Insulet as having medium risk exposure, and we concur. The biggest risk revolves around the potential for product defects. While insulin pumps are not quite equivalent to life-saving devices such as pacemakers or heart valves, problems with product performance could lead to serious patient injury. Some of Insulet's products are approved through the 510(k) process, which offers less protection from legal liability than the premarket approval pathway. Insulet's heavy reliance on Omnipod means a recall would have a material effect on cash flow in the near term. However, we are less convinced that a defective product would necessarily impair the firm's narrow moat, as most defective devices can be addressed with new engineering or manufacturing solutions relatively quickly.

Bull case

Rumblings that Medicare's competitive bidding program for durable medical equipment distributors will include insulin pumps could boost Insulet, as its pumps are distributed through the pharmacy channel.

Insulet created the first tubeless insulin pump on the US market and has a head start on the manufacturing learning curves related to this disposable one-piece unit.

With makers of continuous glucose monitors focused on converting the much larger Type 2 diabetes population, Insulet has benefited as some of these patients from this larger segment also opt to adopt an insulin pump.

Bear case

With only one product and low switching costs for customers, Insulet is vulnerable if larger competitors produce similar or superior tubeless insulin pumps.

When consumers pull back on spending, we've seen some diabetic patients put off purchases of more discretionary devices such as insulin pumps when manual injections provide adequate blood glucose control.

Insulet's hybrid closed-loop algorithm is reputed to be inferior to those offered by competitors. Management has acknowledged that the algorithm needs improvement.

By Debbie S. Wang

Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.

Insulet discussion 0 comments

Add a comment